<DOC>
	<DOCNO>NCT02718846</DOCNO>
	<brief_summary>A multicenter , randomize , open-label clinical study concurrent control group ass effectiveness safety combine therapy Isobide solution Meniace tablet compare monotherapy Meniace tablet patient Meniere 's disease</brief_summary>
	<brief_title>Isobide Solution Meniace Tablets Compared Monotherapy With Meniace Tablets</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>20 80 year age ( full ) A definite Meniere 's disease patient accord diagnostic criterion AAOHNS ( 1995 ) , 2 episode rotary dizziness last 20 minute within last 3 month ( 12 week ) 1 episode hearing loss record audiometry , tinnitus ear fullness . For female subject possibility pregnancy study period , subject whose urine pregnancy test result negative time screen visit . A subject menopause least one year , one possibility become pregnant surgery , one effectively use acceptable contraceptive measure . A subject definitely agree use adequate contraceptive measure clinical study period . A patient history ear surgery A patient history endolymphatic sac surgery A patient use steroid gentamycin eardrum within last 6 month A patient Isobide administer within 3 month time screen A patient infection ear , paranasal sinus upper airway system A patient disease , Meniere 's disease , manifest repetitive dizziness ( e.g . Migrainous vertigo , vertebrobasilar transient ischemic attack , acoustic neuroma ) A patient acute intracranial hematoma ( If drug administer patient suspect acute intracranial hematoma without check existence intracranial hematoma , bleed stop temporarily brain pressure occur intracranial pressure reduce . Thus , eliminate cause bleed administer drug ensure concern rebleeding ) A patient anuria ( urinary output le 100 mL/day ) A severely dehydrated patient ( loss 10 % body weight ) A patient acute pulmonary edema A patient severe heart failure ( New York Heart Association class III high ) A patient adrenal tumor A patient pheochromocytoma A patient hypersensitive ingredient test control drug A patient hereditary disease galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption A woman pregnant breastfeed A patient deem ineligible clinical study analyst</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>